anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Literature regarding the impact of esophagectomy approach on hospitalizations costs and short-term outcomes is limited. Moreover, few have examined how institutional MIS experience affects costs. We thus examined utilization trends, costs, and short-term outcomes of open and minimally invasive (MIS) esophagectomy as well as assessing the relationship between institutional MIS volume and hospitalization costs.
METHODS: All adults undergoing elective esophagectomy were identified from the 2016-2020 Nationwide Readmissions Database. Multiple regression models were used to assess approach with costs, in-hospital mortality, and major complications. Additionally, annual hospital MIS esophagectomy volume was modeled as a restricted cubic spline against costs. Institutions performing > 16 cases/year corresponding with the inflection point were categorized as high-volume hospitals (HVH). We subsequently examined the association of HVH status with costs, in-hospital mortality, and major complications in patients undergoing minimally invasive esophagectomy.
RESULTS: Of an estimated 29,116 patients meeting inclusion, 10,876 (37.4%) underwent MIS esophagectomy. MIS approaches were associated with $10,600 in increased incremental costs (95% CI 8,800-12,500), but lower odds of in-hospital mortality (AOR 0.76; 95% CI 0.61-0.96) or major complications (AOR 0.68; 95% CI 0.60, 0.77). Moreover, HVH status was associated with decreased adjusted costs, as well as lower odds of postoperative complications for patients undergoing MIS operations.
CONCLUSION: In this nationwide study, MIS esophagectomy was associated with increased hospitalization costs, but improved short-term outcomes. In MIS operations, cost differences were mitigated by volume, as HVH status was linked with decreased costs in the setting of decreased odds of complications. Centralization of care to HVH centers should be considered as MIS approaches are increasingly utilized.
An isolated human megakaryocyte-colony stimulating factor (hMeg-CSF protein) preferably purified to homogeneity from urine of aplastic anemia patients is disclosed. The novel hMeg-CSF protein is a basic protein having a pI equal to about 7.2-7.4 as determined by isoelectric focusing and a molecular weight of about 29.000-34.000 daltons as determined by SDS-PAGE when in a glycosylated and sialyated form. The novel hMeg-CSF protein has the ability to induce the formation megakaryocyte-colony forming units in a murine fibrin clot assay in vitro, and the further ability to regulate megakaryocytopoiesis and platelet production in vivo. The hMeg-CSF protein can be further characterized as a glycoprotein having biantennary carbohydrate structures, beta-galactose residues as terminal or penultimate sugars and sialic acid moieties.  The hMeg-CSF protein is believed to have a specific activity of at least about 4.000 CFU-Meg colonies/mg protein in murine fibrin clot assay. Unique pharmaceuticals containing the hMeg-CSF protein for treating animals including humans and methods for isolating the novel hMeg-CSF protein at various levels of purity are also disclosed.
Like some other mucopolysaccharidosis (MPS) syndromes, MPS III (Sanfilippo syndrome) is characterized by a severe cognitive decline ending in dementia and death. Unlike other MPS syndromes, earlier-stage MPS III is also associated with a range of abnormal and disruptive behaviors that can include, but go well beyond, childhood noncompliance and oppositionality. These behaviors, which cause major disruption in the child's familial, school, and community environments, set MPS III apart from the other MPS disorders. These behaviors may also indicate the identity of the neural pathways affected in this disease; their sequence of onsets may indicate the order in which these pathways are affected. We propose to define and categorize the behavioral profile(s) or phenotype(s) of MPS III and correlate them with clinical quantitative neuroimaging in order to understand the neural bases of the disease. In addition, we will use these results to develop a set of sensitive and specific measures that can be easily administered by health care professionals to help monitor the disease and the efficacy of future treatments.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to medical rehabilitation, traumatology and orthopedics, and can be used in rehabilitation treatment of patients after hip replacement, including in patients with osteoporosis and contraindications to electromagnetic physiotherapeutic procedures. That is ensured by the therapeutic course of gravitational therapy 3 weeks after cement replacement of hip joints in amount of 10 procedures every 10–12 minutes with load of 30–35 rpm. 2 weeks after the first course, second and 4 weeks after the second course the third similar course of gravitational therapy is performed. Simultaneously with the beginning of the first course, administering calcium preparation 1,000 mg and 800 IU of vitamin D for 1 year is prescribed. 5 mg of zolenderone acid is administered iv once after 14 days. In the patients after cementless endoprosthesis 3 weeks after the operation, one course of gravitational therapy is performed in number of 15 procedures daily, duration of 12–14 minutes, with load of 30–35 rpm without antiresorptive therapy.EFFECT: method provides effective treatment of the given group of patients by providing conditions for osteointegration of the endoprosthesis components with bone tissue and, indirectly, with complete recovery of the lower extremity function ensured by the selected complex of actions.1 cl, 2 tbl, 2 ex
An improved vector upon introduction into a suitable host containing the thermolabile repressor CI renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator PLOL from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal bindig site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T1T2 rRNA transcription termination sequence; an origin of replication; and a fragment designated CI434 on which is included the gene for the repressor protein and its associated promoter and operator. Additionally, the vector may include a gene associated with a selectable or identifiable phenotypic trait which is manifested when the vector is present in the host. The distance between the 3' end of PLOL and the 5' end of the N utilization site is less than about 80 base pairs. The distance between the 3' end of the N utilization site and the 5' end of the ribosomal binding site is less than about 300 base pairs. Plasmids have been constructed from the vectors and used to produce bovine growth hormones.
Opioid withdrawal symptoms are a major contributing factor for why opioid treatment programs often fail. Individuals with severe opioid withdrawal symptoms may experience shaking, muscle and bone pain, nausea, depression, anxiety, and drug craving. Tramadol is a medication that is currently used to treat moderate to severe pain in individuals with cancer, joint pain, or pain resulting from surgery. Because of its pharmacological profile, tramadol may also be useful in treating opioid withdrawal. Further research is needed to confirm the benefits of tramadol for opioid addicts. The purpose of this study is to evaluate the effectiveness of tramadol at reducing opioid withdrawal symptoms in opioid-dependent individuals.

This 6-week inpatient study will enroll opioid-dependent individuals. Participants will be required to reside at the research clinic for the entire study. All participants will receive morphine maintenance treatment on a daily basis. Twice a week participants will take part in experimental challenge sessions in which they will be randomly assigned to receive varying doses of tramadol, naloxone, morphine, or placebo. These sessions will assess the ability of tramadol to suppress opioid withdrawal symptoms. Participants will complete performance tasks to measure psychomotor and cognitive functioning. Heart rate and blood pressure will be monitored throughout the experimental sessions. A specialized camera will also be used to assess pupillary response of the eyes. Questionnaires and self-reports will be completed to assess medication effects and withdrawal symptoms. Following the end of the study, all participants will be offered outpatient drug abuse treatment.
The hypoxic pattern of glioblastoma (GBM) is known to be a primary cause of radioresistance. Our study explored the possibility of using gene knockdown of key factors involved in the molecular response to hypoxia, to overcome GBM radioresistance. We used the U87 cell line subjected to chemical hypoxia generated by CoCl2 and exposed to 2 Gy of X-rays, as single or combined treatments, and evaluated gene expression changes of biomarkers involved in the Warburg effect, cell cycle control, and survival to identify the best molecular targets to be knocked-down, among those directly activated by the HIF-1α transcription factor. By this approach, glut-3 and pdk-1 genes were chosen, and the effects of their morpholino-induced gene silencing were evaluated by exploring the proliferative rates and the molecular modifications of the above-mentioned biomarkers. We found that, after combined treatments, glut-3 gene knockdown induced a greater decrease in cell proliferation, compared to pdk-1 gene knockdown and strong upregulation of glut-1 and ldha, as a sign of cell response to restore the anaerobic glycolysis pathway. Overall, glut-3 gene knockdown offered a better chance of controlling the anaerobic use of pyruvate and a better proliferation rate reduction, suggesting it is a suitable silencing target to overcome radioresistance.
PURPOSE: An immunosuppressanct composition containing rifampicin is provided to enhance physical bond between p65 and PXR and to prevent or treat various immune diseases. CONSTITUTION: An immunosuppressant composition contains rifampicin as an active ingredient. Rifampicin suppresses TLR2 expression. The composition is used as an agent for preventing or treating immunorejection, allergic diseases, or autoimmune diseases. A composition for suppressing TLR2 gene expression contains the rifampicin as an active ingredient. Rifampicin enhances physical bond between p65 and PXR.
A blinded, randomized, prospective clinical trial is being performed involving Manitoban women over 18 years undergoing unilateral or bilateral breast reconstruction. Women were originally randomized 50/50 to either the DIEP or SIEA group. Due to only about 60-70% of patients randomized to the SIEA group actually receiving the SIEA procedure, the weight of the randomization has now been changed to 70/30 (SIEA/DIEP) for the remainder of the study (approx. 40/110 recruited patients waiting for their OR). Objective isokinetic abdominal strength testing is being done pre-operatively and 3, 6 and 12 months post-operatively. A self-administered validated abdominal wall and breast outcome questionnaire (Breast-Q) is also given preoperatively and at 3 and 12 months postoperatively in . Secondary outcomes measured include: fat necrosis, abdominal wound breakdown, flap loss and seroma rate. Fat necrosis is detected using ultrasonography. Abdominal wound breakdown is measured using calipers. Seroma rates are tabulated and drainage volumes measured. Statistical analyses include a combination of parametric and non-parametric tests.
A complex vaccine which prevents porcine parvovirus and Erysipelothrixrhusiopathiae at the same time is provided to have immunogenicity and stabilize vaccination without immunological interference. A complex vaccine preventing porcine parvovirus and erysipelothrixrhusiopathiae comprises erysipelothrixrhusiopathiae inactivated bacteria antigen, erysipelothrixrhusiopathiae secretion antigen and porcine parvovirus antigen as an immunologically active ingredient. An aluminium hydroxide gel is mixed in the complex vaccine to have 20 volume%. The porcine pavovirus antigen is obtained by infecting a recombinant Baculovirus ] VP2-BV strain into a Sf-9 cell. The erysipelothrixrhusiopathiae inactivated bacteria antigen is obtained by culturing inactivated erysipelothrix rhusiopathiae T2 strain in the medium and inactivating with 0.2% of formalin. The erysipelothrixrhusiopathiae secretion antigen is obtained by centrifuging erysipelothrixrhusiopathiae bacteria bulk, collecting supernatant and filtering with cassette filter.
The study is to compare the safety, efficacy, and superiority of generic mometasone nasal spray to reference products and to placebo in the treatment of seasonal allergic rhinitis. This protocol describes randomized, double-blind, placebo-controlled, 4- treatment group parallel study of 14 days duration preceded by a single blind 7-day placebo run-in period to investigate the clinical equivalence of Mylan's Mometasone Furoate Monohydrate Nasal Spray, 50 ug per actuation to Merck Sharp \& Dohme's (MSD) Nasonex® Nasal Spray, 50 ug per actuation or MSD EU's Nasonex® Nasal Spray Suspension, 50 ug per actuation. In addition, the superiority of the test and reference products to placebo will be assessed. Prior to randomization to one of 4 study groups, each subject will have a 7-day placebo run-in period. Each subject will then receive one of the following treatments: Mylan's Mometasone Furoate Nasal Spray 50 μg/actuation (2 actuations per nostril per day); Merck-US Nasonex® Nasal Spray 50 μg/actuation (2 actuations per nostril per day); Merck-EU's Nasonex® and Nasal Spray Suspension 50 μg/actuation (2 actuations per nostril per day); or Mylan's Placebo Nasal Spray 50 μL/actuation (2 actuations per nostril per day). Active treatment is for 14 days duration. Reflective total nasal scores (rTNSS) will be collected every 12 hours for 21 days.
Chemically, TRH (protirelin) is identified as 5-oxo-L-prolyl-L-histidyl-L-proline amide. It is a synthetic tripeptide that is believed to be structurally identical to the naturally-occurring thyrotropin-releasing hormone produced by the hypothalamus. The CAS Registry Number is 24305-27-9. The structural formula is:

Figure 1

TRH is supplied as a solution of 1 mL in a 5 mL vial. Each vial contains 500 mcg protirelin, 1.8 mg Methylparaben, 0.2 mg Propylparaben, and 9.0 mg Sodium Chloride. TRH is intended for intravenous administration following dilution with 1 mL sterile water for injection.
CBT will be delivered in accordance with published guidelines and protocols that target the dysfunctional reasoning giving rise to obsessional doubts. The first learning point in I-CBT is that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt. The principal focus of treatment is to show that the doubt is 100% irrelevant in the here and now. To this end the reasoning narrative is identified, including the reasoning distortions contained therein, giving undue credibility to the obsessional doubt. The selective nature of the doubt is underlined by showing the client how under most everyday circumstances his/her reasoning is entirely different from the obsessional situation. This stage also educates the client in the thematic nature of the obsessional doubt and how personal themes dictate the idiosyncratic nature of the person's obsession. The final stage of therapy consists of training the client in the proper use of the senses.
In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil 0.2mg, is administered at the end of surgery. In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
The VeSTAL device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
Shaft fractures of the proximal phalanx are common injuries that may significantly affect hand function. Good fracture stability to allow early mobilization of joints and thus early return of function. The objective of this report is to introduce a novel external-fixation technique using the combination of K-wires and cement. For comparison, we also included another group of patients who were treated using a mini plate and screw system. A total of 104 patients (131 fingers) were randomly allocated into group A (56 patients) and B (51 patients). Patients in group A were treated with cemented K-wire fixation; and patients in group B were treated with conventional mini-plate. Bone healing, range of motion of the fingers, costs of treatments, and patient satisfaction were assessed.
The efficacy of Ryzumvi for the reversal of mydriasis was demonstrated in two, randomized, double-masked, vehicle-controlled trials; MIRA-2 (NCT#04620213) and MIRA-3 (NCT#05134974). A total of 553 subjects, aged 12 to 80 years, who had mydriasis induced by instillation of phenylephrine or tropicamide or a combination of hydroxyamphetamine hydrobromide and tropicamide (Paremyd®) were randomized. Subjects with light and dark irides were included in both trials. Two drops (study eye) or one drop (fellow eye) of Ryzumvi or placebo (vehicle) were administered one hour after instillation of the mydriatic agent. The percentage of subjects with study eyes returning to ≤ 0.2 mm from baseline pupil diameter was statistically significantly greater (p < 0.01) at all time points measured from 60 minutes through 24 hours in the Ryzumvi group compared with the placebo (vehicle) group across both of the MIRA-2 and MIRA-3 trials (see Figure 1). 

Figure 1. Percentage of Subjects with Study Eyes Returning to ≤ 0.2 mm from Baseline Pupil Diameter by Time Point in the MIRA-2 and MIRA-3 Trials

The efficacy of MIRA-2 and MIRA-3 also showed that the change from maximum pupil dilation in study eyes and fellow eyes was statistically significantly different between the Ryzumvi-treated group and the placebo-treated group at all time points from 60 minutes through 24 hours post-treatment (p < 0.01). Pupil size at 24 hours was 1 mm smaller than baseline. These results were consistent regardless of whether phenylephrine or tropicamide/Paremyd were used as mydriatic agents (Figure 2, Figure 3; respectively). 

Figure 2: Pupil Dilation by Time Point with Phenylephrine as Mydriatic Agent in MIRA-2 and MIRA-3 Trials (mITT Population)

Figure 3: Pupil Dilation by Time Point with Tropicamide or Paremyd as Mydriatic Agent in MIRA-2 and MIRA-3 Trials (mITT Population)

The efficacy of Ryzumvi was similar for all age ranges including pediatric subjects aged 3 to 17 years. Pediatric subjects aged 12 to 17 years (n = 27) were treated in MIRA-2 and MIRA-3 and pediatric subjects, aged 3 to 11 years (n = 11) were treated in MIRA-4, (NCT#05223478).
Recently, we took care of a teenage boy in our PICU who had been struggling with a lifelong chronic illness and accompanied him and his parents during the last few days of his life. We had the privilege of getting to know him and his parents quite well during the last few years, as he required hospitalization several times during this time. We saw how extremely dedicated his parents had been to him and his care, how they left no stone unturned and sacrificed everything they could to help him have the best quality of life possible. I happened to not be on service, nor know about the moment when he passed away. I also missed when his funeral took place. I wanted to reach out to his parents, to express how much his life and their love for him had meant to me, too, and to find some closure. So I wrote this short poem for them, and for all the other parents, who have to go through the most difficult time a parent can ever go through-as a pediatric intensivist, a Mom who has never been where they had to go, a fellow human being, and a grieving friend.
BACKGROUND: High blood loss is an adverse event related to increased morbidity and poorer outcomes in pancreatic surgery patients. The aim of this study was to identify risk factors and establish a predictive model for high perioperative blood loss (HPBL) in minimally invasive distal pancreatectomy (MIDP).
METHODS: We collected data from 353 patients who underwent MIDP at a university affiliated tertiary hospital between January 2016 and October 2023. Perioperative blood loss was calculated based on pre- and postoperative hemoglobin concentrations according to a combination of the formulas provided by Nadler and Gross. Multivariate logistic regression analyses were performed for the training cohort to identify the clinical factors independently associated with perioperative blood loss (PBL). A predictive nomogram based on these factors was established and validated.
RESULTS: Weight, imaging findings, serum albumin concentration, MIDP experience, spleen treatment, and operation time were independent predictors for HPBL. The established model for predicting HPBL showed that the area under the curve (AUC) was 0.799 (95% CI = 0.746-0.853) and 0.852 (95% CI = 0.760-0.943) for the training cohort and validation cohort, respectively. When utilized to predict blood transfusion, the AUC was 0.778 (95% CI = 0.691-0.865) in the training cohort and 0.818 (95% CI = 0.681-0.955) in the validation cohort. Patients with a high predicted risk had significantly higher incidences of postoperative pancreatic fistula, intra-abdominal infection, and longer hospital stays than patients with a low risk.
CONCLUSIONS: We established and validated a model for predicting HPBL in MIDP patients. This novel model may have future utility when generating surgical strategies.
A skin care evaluation method, which is adapted for an electronic device to evaluate a skin care procedure including a plurality of skin care behaviours. The skin care evaluation method includes following steps. A plurality of image information is sequentially captured at a plurality of image capturing time. A plurality of user actions corresponding to the image information is analyzed, where a plurality of consecutive image information of the image information corresponds to one of the user actions. The image information is classified to the skin care behaviours according to the user action corresponding to each of the image information. Each of the skin care behaviours corresponds to a plurality of the user actions. A duration of each of the skin care behaviours is calculated according to the image capturing time of the image information classified to each of the skin care behaviours. An electronic device using the skin care evaluation method is also provided.
In this national, multicenter study the study group will investigate whether patients with rectal adenocarcinoma undergoing a resection with an anastomosis will benefit from a diverting stoma or not, by studying how choice of surgery affects complications. In addition the study group will investigate complication rates and HRQoL among patients receiving a permanent colostomy and compare this to patients who have received an anastomosis. The investigators know that there are different approaches to the use of stomas (both permanent and diverting) between different hospitals. The investigators aim to discover potential differences in complication rates, length of stay and HRQoL among these patients and compare this to the chosen strategy. Health related quality of life will be measured using the EORTC CR 29 and EORTC CR 30 questionnares. Bowel function will also be monitored using the LARS (low anterior resection syndrome) score.